Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2025
Limitations of Subgroup Safety Analyses for Drug-Drug Interaction Evaluation: Insights from the Talazoparib P-gp Inhibitor Case.
Journal: Journal of clinical pharmacology
Published: November 13, 2025
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.
Journal: Journal of pharmacokinetics and pharmacodynamics
Published: June 17, 2025
Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed Bioequivalence.
Journal: CPT: pharmacometrics & systems pharmacology
Published: May 08, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.
Journal: European urology oncology
Published: April 08, 2025
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 29, 2024
Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses.
Journal: The oncologist
Published: May 06, 2022
Pregnancy outcomes in patients treated with bosutinib.
Journal: International journal of hematologic oncology
Published: October 02, 2020
Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
Journal: The oncologist
Published: June 27, 2019
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: November 10, 2018
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Journal: Haematologica
Published: April 21, 2017
Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma.
Journal: Clinical genitourinary cancer
Published: May 11, 2015
Last Updated: 09/26/2026